RHJA
KNSA icon

Rice Hall James & Associates’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Rice Hall James & Associates’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40M Buy
624,928
+16,512
+3% +$857K 1.95% 9
2026
Q1 		$29.3M Buy
608,416
+11,985
+2% +$531K 1.63% 13
2025
Q4 		$24.6M Buy
596,431
+18,609
+3% +$746K 1.35% 22
2025
Q3 		$22.4M Sell
577,822
-60,411
-9% -$1.96M 1.22% 23
2025
Q2 		$17.7M Buy
638,233
+13,688
+2% +$348K 0.95% 31
2025
Q1 		$13.9M Sell
624,545
-18,207
-3% -$375K 0.82% 38
2024
Q4 		$12.7M Sell
642,752
-6,878
-1% -$157K 0.7% 43
2024
Q3 		$16.2M Buy
649,630
+49,000
+8% +$1.19M 0.88% 29
2024
Q2 		$11.2M Sell
600,630
-18,168
-3% -$340K 0.67% 44
2024
Q1 		$12.2M Sell
618,798
-17,231
-3% -$337K 0.7% 41
2023
Q4 		$11.2M Sell
636,029
-14,337
-2% -$236K 0.65% 44
2023
Q3 		$11.3M Sell
650,366
-9,758
-1% -$164K 0.72% 41
2023
Q2 		$9.29M Buy
660,124
+4,468
+0.7% +$59.8K 0.53% 51
2023
Q1 		$7.05M Sell
655,656
-41,506
-6% -$547K 0.4% 60
2022
Q4 		$10.4M Sell
697,162
-52,771
-7% -$768K 0.6% 48
2022
Q3 		$9.63M Sell
749,933
-64,740
-8% -$738K 0.56% 49
2022
Q2 		$7.89M Buy
814,673
+2,751
+0.3% +$25.7K 0.38% 64
2022
Q1 		$8.07M Buy
811,922
+99,115
+14% +$1.05M 0.32% 74
2021
Q4 		$8.39M Sell
712,807
-24,567
-3% -$302K 0.3% 72
2021
Q3 		$8.4M Buy
737,374
+3,008
+0.4% +$39.2K 0.31% 71
2021
Q2 		$10.2M Buy
734,366
+68,013
+10% +$1.03M 0.36% 66
2021
Q1 		$12.3M Buy
666,353
+66,836
+11% +$1.37M 0.4% 61
2020
Q4 		$10.6M Buy
+599,517
New +$10.5M 0.37% 62

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Rice Hall James & Associates's KNSA Position: Q2 2026 in Review

Rice Hall James & Associates increased its Kiniksa Pharmaceuticals (KNSA) stake by 2.7% in Q2 2026, buying an estimated $857K and bringing the position to 624,928 shares worth $40M. The position accounts for 1.95% of the portfolio, ranked #9.

Rice Hall James & Associates first reported a position in KNSA in Q4 2020 and has held it in 23 quarters since. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Rice Hall James & Associates held 624,928 shares of Kiniksa Pharmaceuticals worth $40M as of Q2 2026.
  • Rice Hall James & Associates bought 16,512 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $857K.
  • Kiniksa Pharmaceuticals made up 1.95% of Rice Hall James & Associates's portfolio in Q2 2026, its #9 holding.
  • Rice Hall James & Associates first reported a position in Kiniksa Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • 267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.